Trials / Completed
CompletedNCT01255696
Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Alvine Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALV003 | |
| BIOLOGICAL | ALV003 placebo |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-05-01
- Completion
- 2011-06-01
- First posted
- 2010-12-07
- Last updated
- 2012-08-06
Locations
3 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT01255696. Inclusion in this directory is not an endorsement.